EP1263453A4 - Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix - Google Patents
Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrixInfo
- Publication number
- EP1263453A4 EP1263453A4 EP01939971A EP01939971A EP1263453A4 EP 1263453 A4 EP1263453 A4 EP 1263453A4 EP 01939971 A EP01939971 A EP 01939971A EP 01939971 A EP01939971 A EP 01939971A EP 1263453 A4 EP1263453 A4 EP 1263453A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- regulating
- biologically active
- active compounds
- polymer matrix
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17413799P | 1999-12-31 | 1999-12-31 | |
US174137P | 1999-12-31 | ||
PCT/US2001/000030 WO2001049249A2 (en) | 1999-12-31 | 2001-01-02 | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1263453A2 EP1263453A2 (en) | 2002-12-11 |
EP1263453A4 true EP1263453A4 (en) | 2008-02-20 |
Family
ID=22634986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01939971A Ceased EP1263453A4 (en) | 1999-12-31 | 2001-01-02 | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1263453A4 (en) |
JP (1) | JP2003519164A (en) |
AU (1) | AU784226B2 (en) |
CA (1) | CA2396037A1 (en) |
WO (1) | WO2001049249A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7326425B2 (en) | 1999-12-31 | 2008-02-05 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
DK1881823T3 (en) | 2005-05-17 | 2015-03-02 | Sarcode Bioscience Inc | COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS |
EP2114298B1 (en) | 2006-02-08 | 2022-10-19 | Medtronic, Inc. | Temporarily stiffened mesh prostheses |
US8315700B2 (en) | 2006-02-08 | 2012-11-20 | Tyrx, Inc. | Preventing biofilm formation on implantable medical devices |
US9265865B2 (en) | 2006-06-30 | 2016-02-23 | Boston Scientific Scimed, Inc. | Stent having time-release indicator |
EP2079387B1 (en) | 2006-11-06 | 2017-04-12 | Tyrx, Inc. | Mesh pouches for implantable medical devices |
US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
EP2129339B1 (en) | 2007-03-29 | 2015-03-04 | Tyrx, Inc. | Biodegradable, polymer coverings for breast implants |
US9491966B2 (en) | 2007-05-02 | 2016-11-15 | Tyrx, Inc. | Dihydroxybenzoate polymers and uses thereof |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (en) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
MX2010004281A (en) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Compositions and methods for treatment of diabetic retinopathy. |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8652525B2 (en) | 2008-07-10 | 2014-02-18 | Tyrx, Inc. | NSAID delivery from polyarylates |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP5671463B2 (en) | 2008-09-22 | 2015-02-18 | タイレックス・インコーポレイテッドTyrx Inc. | Linear polyester amides from aminophenol esters |
US9839628B2 (en) | 2009-06-01 | 2017-12-12 | Tyrx, Inc. | Compositions and methods for preventing sternal wound infections |
JP5847706B2 (en) * | 2009-06-01 | 2016-01-27 | タイレックス・インコーポレイテッドTyrx Inc. | Compositions and methods for preventing sternum wound infections |
EP2459617A4 (en) * | 2009-07-31 | 2016-06-08 | Univ Rutgers | Bioresorbable polymers synthesized from monomer analogs of natural metabolites |
US8409279B2 (en) | 2009-10-01 | 2013-04-02 | Lipose Corporation | Breast implant implantation method and apparatus |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
EP2609162B1 (en) | 2010-08-25 | 2018-12-12 | Tyrx, Inc. | Novel medical device coatings |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
AU2011326417A1 (en) | 2010-11-12 | 2013-05-09 | Tyrx, Inc. | Anchorage devices comprising an active pharmaceutical ingredient |
JP2014523330A (en) | 2011-07-20 | 2014-09-11 | タイレックス・インコーポレイテッド | Drug-eluting mesh to prevent infection of indwelling transcutaneous devices |
JP6607780B2 (en) | 2012-07-25 | 2019-11-20 | サルコード・バイオサイエンス・インコーポレイテッド | LFA-1 inhibitors and polymorphs thereof |
WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014137454A1 (en) | 2013-03-07 | 2014-09-12 | Tyrx, Inc. | Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2926691A1 (en) | 2013-10-10 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
CN105431178A (en) | 2013-11-08 | 2016-03-23 | 泰尔克斯公司 | Antimicrobial compositions and methods for preventing infection in surgical incision sites |
EP3177319A1 (en) * | 2014-08-04 | 2017-06-14 | Janssen Sciences Ireland UC | Compacted solid dosage form |
CA3009814A1 (en) | 2016-01-11 | 2017-07-20 | Synergy Pharmaceuticals, Inc. | Formulations and methods for treating ulcerative colitis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587507A (en) * | 1995-03-31 | 1996-12-24 | Rutgers, The State University | Synthesis of tyrosine derived diphenol monomers |
WO1997019996A1 (en) * | 1995-11-27 | 1997-06-05 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
WO1998036013A1 (en) * | 1997-02-18 | 1998-08-20 | Rutgers, The State University | Monomers derived from hydroxy acids and polymers prepared therefrom |
WO1999024107A1 (en) * | 1997-11-07 | 1999-05-20 | Rutgers, The State University | Biodegradable, anionic polymers derived from the amino acid l-tyrosine |
WO1999029758A1 (en) * | 1997-12-12 | 1999-06-17 | Samyang Corporation | Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
WO1999052962A1 (en) * | 1998-04-13 | 1999-10-21 | Rutgers, The State University | The construction of copolymer libraries |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19719817A1 (en) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids |
AU2373200A (en) * | 1999-02-05 | 2000-08-25 | Alien Technology Corporation | Apparatuses and methods for forming assemblies |
-
2001
- 2001-01-02 WO PCT/US2001/000030 patent/WO2001049249A2/en active Application Filing
- 2001-01-02 EP EP01939971A patent/EP1263453A4/en not_active Ceased
- 2001-01-02 CA CA002396037A patent/CA2396037A1/en not_active Abandoned
- 2001-01-02 AU AU29255/01A patent/AU784226B2/en not_active Expired
- 2001-01-02 JP JP2001549618A patent/JP2003519164A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587507A (en) * | 1995-03-31 | 1996-12-24 | Rutgers, The State University | Synthesis of tyrosine derived diphenol monomers |
WO1997019996A1 (en) * | 1995-11-27 | 1997-06-05 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
WO1998036013A1 (en) * | 1997-02-18 | 1998-08-20 | Rutgers, The State University | Monomers derived from hydroxy acids and polymers prepared therefrom |
WO1999024107A1 (en) * | 1997-11-07 | 1999-05-20 | Rutgers, The State University | Biodegradable, anionic polymers derived from the amino acid l-tyrosine |
WO1999029758A1 (en) * | 1997-12-12 | 1999-06-17 | Samyang Corporation | Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
WO1999052962A1 (en) * | 1998-04-13 | 1999-10-21 | Rutgers, The State University | The construction of copolymer libraries |
Non-Patent Citations (1)
Title |
---|
CHA Y ET AL: "a one-week subdermal delivery system for l-methadone based on biodegradable microcapsules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 1, April 1988 (1988-04-01), pages 69 - 78, XP002143620, ISSN: 0168-3659 * |
Also Published As
Publication number | Publication date |
---|---|
AU2925501A (en) | 2001-07-16 |
JP2003519164A (en) | 2003-06-17 |
AU784226B2 (en) | 2006-02-23 |
WO2001049249A2 (en) | 2001-07-12 |
CA2396037A1 (en) | 2001-07-12 |
WO2001049249A3 (en) | 2002-01-17 |
EP1263453A2 (en) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1263453A4 (en) | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix | |
AU5914999A (en) | Controlled release drug delivery | |
HUP0301242A3 (en) | Controlled release drug dosage form | |
IL132453A0 (en) | Gastroretentive controlled release microspheres for improve drug delivery | |
AU2180400A (en) | A pharmaceutical combination for the treatment of depression | |
IL121275A (en) | Controlled release formulation for poorly soluble basic drugs | |
AU5335698A (en) | Pharmaceutical formulations with delayed drug release | |
AU7839900A (en) | Reusable medication delivery device | |
EP1251864A4 (en) | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release | |
IL145581A0 (en) | A modified release pharmaceutical composition comprising amoxycillin | |
AU4464897A (en) | Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix | |
AU4328800A (en) | Pharmaceutical formulation | |
AU2003240654A1 (en) | Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release | |
ZA988718B (en) | Drug formulation having controlled release of active compound | |
IL134075A0 (en) | Analgesic with controlled active substance release | |
AU5812800A (en) | Pharmaceutical preparation | |
AU2773597A (en) | Pharmaceutical compositions for the sustained release of insoluble active principles | |
AU1650401A (en) | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | |
AU5820900A (en) | Capsule for the controlled release of active substances | |
AU5026599A (en) | A wet granulation method for preparing a stable pharmaceutical formulation | |
AU1650501A (en) | 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient | |
IL148543A0 (en) | Pharmaceutical carrier formulation | |
AU7887400A (en) | A slow release pharmaceutical composition | |
AU3839900A (en) | Pharmaceutical formulation | |
AU6866700A (en) | Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020723 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
R17P | Request for examination filed (corrected) |
Effective date: 20020723 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080121 |
|
17Q | First examination report despatched |
Effective date: 20080718 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20110207 |